Pharmaceutical Act §§66–68 — The Statute and the Two Cases That Shaped the Industry Norms— Why the prohibitions on exaggerated, special-disease, and pre-approval advertising are written the way they are

01Pharmaceutical Act §§66–68 — the full picture

First, the three articles laid out. The legal text is short. Sixty-plus years of postwar drug-disaster history and industry response are compressed into that brevity.

The common subject across all three is "no person". Not only pharma companies — healthcare professionals, media, researchers, and even SNS posters are within scope. This is the law's response to the singular nature of medicine as a good: a patient cannot verify quality on their own, and the consequences land on life itself.

02§66 (exaggerated advertising) — a wide net that catches implication

The key phrase in §66 is "whether explicit or implicit". It is a declaration that the article's reach extends from "the words themselves" to "the impression that lingers in the reader's head".

Four typical violation patterns:

• Guarantee-like expressions: "best", "only", "100%", "definitely" — assertions beyond the medical evidence
• Implied exaggerated effect: cropping graph axes; emphasizing differences that aren't significant; cherry-picking comparators
• Off-label-suggesting phrasing: "there are also possibilities …" / "research shows …" — hinting outside the approved scope
• Downplayed safety: muting adverse events while amplifying efficacy — unbalanced framing

Another feature of §66 is that the target — "name, manufacturing method, efficacy, effect, or performance" — is broad. Even a general corporate brand campaign falls into §66's range the moment it speaks to a drug's efficacy. That is why disease-awareness materials directed at patients fall under review the moment the product name is implied.

03§68 (pre-approval advertising) — forbidding "expectation-building before launch"

§68 is extremely simple: "No one may advertise an unapproved drug." The text is short, but the operational reach is wide and the interpretive edge cases are subtle.

The logic is clear. Before approval, efficacy and safety are not publicly confirmed. Advertising "this works" pre-approval pushes patients to expect an unverified treatment and steers clinicians toward off-label choices. The approval system itself is hollowed out.

What makes operations hard is the boundary of "advertising". The guiding test is whether an inappropriate intent is present, whether implicit or explicit — "does this have the potential to act on a patient's or a clinician's treatment choice, whether by implication or by direct statement? Does the potential extend beyond a particular expression and reach the level of context?" If, under a third party's critical gaze, no reasonable explanation can be offered to those questions, then it is to be treated as advertising.

04§67 (special-disease restrictions) — the line for general advertising

§67 restricts advertising to non-healthcare-professionals for drugs intended for cancer, sarcoma, leukemia, and similar special diseases. The background: when patients and families search desperately for any treatment, commercial misdirection has higher impact and the law tilts the asymmetry.

The cabinet order specifies the special diseases, which the MHLW explanatory notice (薬生監麻発0929第5号) lists as cancer, sarcoma, and leukemia; the drugs covered are those designated by MHLW ordinance from among the drugs used for these diseases. Information to healthcare professionals (specialty journals, medical societies, HCP-only seminars) is allowed; general-newspaper advertising, TV commercials, and patient-directed web ads are, in principle, prohibited or under heavy restriction.

05The Diovan affair (2014) — the first major trust crisis the industry faced

The essence of Diovan was not "an ordinary advertising violation". The structural fact that the independence of pharma companies and investigator-initiated clinical research had been eroded came to light.

Key points:

• Company staff entered the studies as university "non-tenure researchers" and took part in data analysis
• Study results were written up emphasizing cardiovascular-event suppression
• The papers were then cited in promotional materials, distributed by MRs to clinicians nationwide
• Multiple papers were later retracted; Tokyo prosecutors indicted the company and a former employee under the Pharmaceutical Act

The 2017 Tokyo District Court ruling reached not-guilty on the §66 elements (the words "whether explicit or implicit, exaggerated") but did not erase the social blame on the industry. If anything, the ruling accelerated the conclusion that "the Pharmaceutical Act alone is not enough".

06The Blopress affair (2014) — exploiting "room for interpretation"

The Blopress affair, alongside Diovan, shook the industry. The key fact was that "the data itself was not falsified, but the presentation produced a misleading impression".

Concretely:

• The study's outcome showed no statistically significant difference between groups
• But the graph split the time series into early and late halves, and showed only the latter
• In the late half, Blopress numerically looked superior — the "golden cross" framing
• A non-significant result was thus left in readers' heads as "superior"

The MHLW issued a business-improvement order to Takeda in 2014. Even when the underlying fact is correct, the manner of presentation can constitute implicit exaggeration. This became a key operational interpretation of §66's "whether explicit or implicit" language, and material-review work still references it.

07The industry's response — Clinical Trials Act and the Sales-Information-Provision Activity Guideline

Diovan and Blopress left the industry with the heavy lesson that the Pharmaceutical Act alone is institutionally insufficient. The response was two new institutions.

Clinical Trials Act (effective 2018)

A direct institutional response to Diovan. Main contents:

• Notification for "specified clinical trials" (those using unapproved or off-label drugs, and those receiving pharma funding)
• Mandatory prior review by an accredited Certified Review Board (CRB)
• Strict disclosure of pharma research funding and human-resource support
• Criminal penalties for violations

The Clinical Trials Act, in essence, uses law to install a "distance" between pharma and investigator-initiated research. It blocks structurally the kind of deep embedding company staff achieved at universities in Diovan.

Sales-Information-Provision Activity Guideline ("HanteiG", issued 2018 / effective 2019)

HanteiG is the response to Blopress. The MHLW drew the operational boundary lines around MR information-provision activities. Main contents:

• Information stays within the approved scope
• Prohibition of unsolicited delivery of unapproved / off-label information
• Prohibition of cherry-picking / emphasis manipulation of research results (squarely directed at the Blopress graphics)
• Internal monitoring (mandatory in-house review committees)
• Penalties up to business-suspension orders and reports to management

HanteiG translates the Pharmaceutical Act §66's abstract "exaggerated advertising" into a concrete list of prohibited acts. Material reviewers operate by combining the Act and HanteiG. See Material Review Vol. 2 for details.

08The essence of §§66–68 — discipline placed on a credence good

Once the history is in view, §§66–68 are clearly not just "advertising rules". They are an institutional response to the structure of credence goods covered in Vol. 2.

The logic:

• Medicine is a credence good the patient cannot verify
• In credence-good markets, the seller's words strongly determine the buyer's decision
• If excessive bias (exaggeration, falsehood) enters the seller's words, the market malfunctions
• §§66–68 are devices that legally suppress that verbal bias

So §§66–68 do not "restrict pharma's freedom of expression". They protect the conditions that let the credence-good market keep functioning. Within the balance between expression freedom and public safety, the law tilts toward the latter — that is the legislative intent.

09The norm of a pharma company as a for-profit corporation

A pharma company is a stock corporation. There is a duty to return profit to shareholders. At the same time, the Pharmaceutical Act §§66–68 impose a discipline that "restrains words". The two stand in tension.

Three ways to resolve the tension:

Path 1 — make the trade-off between "short-term profit" and "long-term trust" explicit: a temporary win in expression erodes industry-wide trust and, in the long term, shrinks the market. Novartis's post-Diovan revenue drop is one empirical instance of this circuit. Bring the short-term temptation onto the same balance sheet as the long-term trust cost.

Path 2 — embed conflict of interest (COI) into the corporate culture: sales vs. R&D, development vs. promotion — every function has its own COI. Don't deny it. Take "COI is always present" as a given and build suppression devices into the institution: ethics committees, independent ad review, third-party audits.

Path 3 — leaders keep speaking the "weight of words": §§66–68 reach front-line staff as articles of law. But as long as leadership keeps saying "our words reach the patient's life", the text moves from rule to culture. Once it is culture, the field tilts to the safe side even inside the interpretive room of the text.

The pursuit of corporate profit and the discipline of a credence-good business do not, fundamentally, contradict. In the long run, preserving trust is itself the largest revenue source. The contradiction is only visible at the short horizon. Leadership's role is to keep transmitting this difference of time scale to both the field and the shareholders.

10Field practice — the four-layer structure and four questions

To land this in practice, the hierarchical structure of the regulations must first be in your head. Materials and information-provision activities are not judged against a single article. They pass through several layers in sequence, each lower layer translating the spirit of the higher one into concrete behavior.

The four layers are concentric. Each lower layer operationalizes the spirit of the one above. So if you pass at the lowest layer (HanteiG), you will be aligned with the higher ones too. Conversely, passing only the upper layers can still stall at the lower ones. Always pass through in the reverse direction — HanteiG → Appropriateness Standards → §66/§68. This is the operational craft.

Built on that hierarchy, four questions. Build the habit of asking each, even for a single second, while reviewing materials or planning information-provision activities.

1. "Is this expression explicit or implicit?" — keeping §66's reach (which includes implicit) in view
2. "Is this chart's axis a faithful presentation of the data, or impression management?" — Blopress's lesson; the core of the Appropriateness Standards
3. "Beyond Pharmaceutical Act §66/§68 and the Appropriateness Standards, is this sales-information-provision activity also appropriate under HanteiG?" — a reverse-direction traversal of the four layers
4. "If this message spread on SNS, how would it look to a patient?" — the lens of the social-trust era

Asking these four daily changes judgment speed by an order of magnitude three years later. This is the move from "remembering the law as text" to "embodying the four-layer hierarchy and traversing it instantly".